Navigation Links
Rigel Announces Pricing of Public Offering of Common Stock
Date:5/26/2011

).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Rigel Pharmaceuticals, Inc.
Rigel, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as for muscle disorders.

Forward-Looking Information is Subject to Risk and Uncertainty

Certain of the statements made in this press release are forward looking, such as those, among others, relating to Rigel's expectations regarding the completion, timing and size of the public offering and the amount of gross proceeds to be received. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to market and other conditions, the satisfaction of customary closing conditions related to the public offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that Rigel will be able to complete the public offering at the anticipated size or on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release.  Additional risks and uncertainties relating to the offering, Rigel and its business can be found under the heading "Risk Factors" in Rigel's Quarterly Report on Form 10-Q filed with the SEC on May 3, 2011 and other filings with the SEC, in the preliminary prospectus supplement related to the o
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rigel Announces Proposed Public Offering of Common Stock
2. Rigel to Present at Bank of America Merrill Lynch Health Care Conference
3. Rigel Announces First Quarter Financial Results
4. Rigel Announces Fourth Quarter and Year End 2010 Financial Results
5. Rigel to Present at Three Upcoming Investor Conferences
6. Rigel Announces Participation at Two Investor Conferences
7. Rigel to Present at JP Morgan Healthcare Conference
8. Rigel Announces Third Quarter 2009 Financial Results
9. Rigel Announces Presentations at Two Investor Conferences
10. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
11. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   Assurex Health, a personalized medicine ... providers for behavioral health and chronic pain conditions, ... in equity financing from new and existing investors, ... and Chief Executive Officer. The financing ... Assurex Health,s GeneSight ®  products.  GeneSight,s ...
(Date:12/24/2014)... China , Dec. 23, 2014 ... pharmaceutical company that specializes in patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) today announced that the Company ... its Good Manufacturing Practice (GMP) certificate of TPI,s ... Drug Administration,s (CFDA). The public notice period is ...
(Date:12/24/2014)... , Dec. 23, 2014  Medical Science Liaisons ... the key link between the medical device industry and ... more in the coming years as the device industry ... According to research by benchmarking firm, Best Practices, ... gain an important edge is by harnessing new technology ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Role of Medical Science Liaisons Evolving in Medical Device Sector 2
... WIRE)--Jun 29, 2007 - Reata,Pharmaceuticals, Inc. today ... their lead anti-cancer agent, the,Synthetic Triterpenoid RTA ... caused by traditional cancer treatments. This,data was ... Multinational,Association of Supportive Care in Cancer (MASSC) ...
... /PRNewswire-FirstCall/ -- Advanced Life,Sciences Holdings, Inc. , today announced ... at 10:00 am (EDT) on Monday, July,2, 2007 to ... pivotal,Phase 3 clinical trials designed to assess the safety ... of community acquired pneumonia (CAP). , Conference Call Details: ...
Cached Medicine Technology:RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments 2RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments 3Advanced Life Sciences to Host Conference Call to Discuss Data From,Cethromycin's First of Two Phase 3 Pneumonia Trials 2
(Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
(Date:12/25/2014)... -- The risk of burns from fires and cooking ... be extra cautious, an expert says. "Between Thanksgiving ... in patients coming in with burns," said Dr. Steven ... Burn Center of Stony Brook University Hospital in New ... but if not careful, could quickly turn tragic," Sandoval ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... be closing in on a "fountain of youth" drug that ... of older adults, a new study suggests. Seniors received ... drug that targets a genetic signaling pathway linked to aging ... The experimental medication, a version of the ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Each year ... and 2 million hospital admissions across the nation (according ... ). The CDC’s National Hospital Ambulatory Medical Care ... a survey conducted in 2010. They estimated that there ... that resulted in a primary diagnosis of broken bone ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... One in eight new moms experience postpartum major depressive disorder ... 80 percent of women experience depressive symptoms postpartum, with one in ... Caused by multiple factors, including stress and hormone changes in the ... blues, to major depression and in rare circumstances, the most severe ...
... CRUZ, CA--The National Institute on Drug Abuse (NIDA) has awarded ... Berman, professor and chair of biomolecular engineering at the Jack ... Cruz. With the new five-year grant, Berman,s group ... August issue of the Journal of Virology . The ...
... Mass., Sept. 9 Echo Therapeutics, Inc. (OTC Bulletin ... Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous ... for transdermal drug delivery, announced today that it has ... 2009 Annual Global Investment Conference. Patrick T. Mooney, ...
... ... and Trademark office for knotless surgery tissue fixation to KFx Medical. , ... San Diego, CA (PRWEB) September 9, 2009 -- ... No. 7,585,311 by the United States Patent and Trademark office. The key patent covers a ...
... , More than 1.3 million Americans ... , , WASHINGTON, Sept. 9 Leading opponents of ... National Center for Policy Analysis (NCPA) and Salem Radio Network delivered the ... Now" petition to Congress at a rally held on Capitol Hill. , ...
... SAN DIEGO, Sept. 9 US Farms, Inc. (Pink ... that it has filed a Trademark Application in the United States, ... http://tarr.uspto.gov/servlet/tarr?regser=serial&entry=77821663 . , , ... a diversified Farming, Nursery and Wellness Company. The company grows, markets ...
Cached Medicine News:Health News:Prentice Women's Hospital Launches New Initiative to Better Identify and Address Postpartum Depression 2Health News:Prentice Women's Hospital Launches New Initiative to Better Identify and Address Postpartum Depression 3Health News:Prentice Women's Hospital Launches New Initiative to Better Identify and Address Postpartum Depression 4Health News:$3.5 million NIH grant supports AIDS vaccine research at UC Santa Cruz 2Health News:$3.5 million NIH grant supports AIDS vaccine research at UC Santa Cruz 3Health News:Echo Therapeutics Announces New Presentation Time at Rodman & Renshaw 2009 Annual Global Investment Conference 2Health News:KFx Medical Awarded Key Patent for Knotless Tissue Fixation and Double Row Rotator Cuff Surgery 2Health News:National Center for Policy Analysis and Salem Radio Network Deliver Million-Plus Signature Petition Opposing Government Run Health Care 2Health News:National Center for Policy Analysis and Salem Radio Network Deliver Million-Plus Signature Petition Opposing Government Run Health Care 3Health News:US Farms, Inc. Files Trademark Application for Aloe365 2
The Thermal pads were designed to simulate water immersion, the most effective method of transferring energy non-invasively....
This blanket is ideal for warming the large child or small adult during upper body surgery....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
Medicine Products: